FGP
MRK icon

Freestone Grove Partners’s Merck MRK Stock Holding History

Freestone Grove Partners’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.49M Buy
+27,158
New +$3.18M 0.02% 371
2025
Q2 		– Sell
-10,977
Closed -$985K – 794
2025
Q1 		$985K Buy
+10,977
New +$1.02M 0.01% 351

Other funds holding MRK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Freestone Grove Partners's MRK Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Merck (MRK) in Q2 2026: 27,158 shares worth $3.49M. The stake represents 0.02% of the portfolio and ranks #371 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in MRK as recently as Q1 2025.

Freestone Grove Partners first reported a position in MRK in Q1 2025 and has held it in 2 quarters since. 3,833 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Freestone Grove Partners held 27,158 shares of Merck worth $3.49M as of Q2 2026.
  • Merck was a new Freestone Grove Partners position in Q2 2026.
  • Merck made up 0.02% of Freestone Grove Partners's portfolio in Q2 2026, its #371 holding.
  • Freestone Grove Partners first reported a position in Merck in Q1 2025 and has held it in 2 quarters since.
  • 3,833 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.